In 2024, Iceland leads the global market for modulators of the genital system and sex hormones with a per capita spending of $20.5, followed by Canada at $15.1 and Ireland at $14.4. Over the last year, Ireland experienced a significant growth of 11.92%, whereas most countries showed negative variations, including Canada (-2.57%), Norway (-2.27%), and Belgium (-1.69%). Australia showed a modest increase of 3.02%, and Germany had a slight rise of 1.11%. Spain and Hungary had notable declines at -4.01% and -4.14%, respectively.
Over the last five years, there have been varied trends across countries. While some markets, such as Ireland and New Zealand, have consistently grown, others like Greece and Austria have seen steady declines. The last-year trends emphasize Australia’s consistent growth and Germany’s resilience amidst a general downward trend in Europe.
Future trends to watch include technological advancements in hormone modulators, shifts in healthcare policies regarding reproductive health, and increased health consciousness influencing market dynamics. Potential growth in underdeveloped markets and ongoing research in hormonal therapies could pivot the landscape significantly.
Top countries in Modulators of the Genital System and Sex Hormones Sales by Country
| # | 10 Countries | US Dollars Per Capita | Last Year | YoY | 5-years CAGR | |
|---|---|---|---|---|---|---|
| 1 | 1 Iceland | 20.5 | 2023 | 0% | +0.3% | View data |
| 2 | 2 Canada | 15.1 | 2023 | 0% | -2.57% | View data |
| 3 | 3 Ireland | 14.4 | 2023 | +10.77% | +11.92% | View data |
| 4 | 4 Norway | 11.5 | 2023 | +4.55% | -2.27% | View data |
| 5 | 5 Belgium | 10.1 | 2023 | +2.02% | -1.69% | View data |
| 6 | 6 Australia | 9.4 | 2023 | +1.08% | +3.02% | View data |
| 7 | 7 Czech Republic | 8.5 | 2023 | +13.33% | -1.57% | View data |
| 8 | 8 Germany | 5.6 | 2023 | 0% | +1.11% | View data |
| 9 | 9 Estonia | 4.6 | 2023 | 0% | -0.43% | View data |
| 10 | 10 Greece | 3.8 | 2023 | 0% | -3.75% | View data |
